UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 324

Sortiert nach

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Annals of the rheumatic diseases, 2012-06, Vol.71 (6), p.875-877

2012

Volltextzugriff (PDF)

Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra)

Rheumatology, 2011-02, Vol.50 (2), p.283-292

2011

Volltextzugriff (PDF)

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Annals of the rheumatic diseases, 2008-03, Vol.67 (3), p.302-308

2008

Volltextzugriff (PDF)

Usefulness of monitoring of B cell depletion in rituximab‐treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study

Clinical and experimental immunology, 2015-04, Vol.180 (1), p.11-18

2015

Volltextzugriff (PDF)

Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis

Rheumatology, 2011-06, Vol.50 (6), p.1137-1147

2011

Volltextzugriff (PDF)

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

Annals of the rheumatic diseases, 2012-11, Vol.71 (11), p.1815-1819

2012

Volltextzugriff (PDF)

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (6), p.1108-1113

2016

Volltextzugriff (PDF)

Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra

Rheumatology (Oxford, England), 2007-12, Vol.46 (12), p.1860-1862

2007

Volltextzugriff (PDF)

FRI0069 Performance of rapid radiographic progression prediction matrices in the early rheumatoid arthritis patients of the espoir cohort

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.332-332

2013

Volltextzugriff (PDF)

Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome

Clinical and experimental immunology, 2007-05, Vol.148 (2), p.281-287

2007

Volltextzugriff (PDF)

Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis

Rheumatology, 2008-08, Vol.47 (8), p.1208-1212

2008

Volltextzugriff (PDF)

Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three‐year prospective study in community‐recruited patients

Rheumatology (Oxford, England), 2003-08, Vol.42 (8), p.939-946

2003

Volltextzugriff (PDF)

AB0248 Clinical Significance of Soluble Vascular Endothelial-Cadherin and Anti-Vascular Endothelial-Cadherin Antibody in Rheumatoid Arthritis Treated with Etanercept or Adalimumab

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.974-974

2015

Volltextzugriff (PDF)

FRI0154 Incidence of Cancers in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.478-479

2015

Volltextzugriff (PDF)

OP0035 Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.78-79

2015

Volltextzugriff (PDF)

FRI0215 Transitional and memory b cell analysis is an essential tool to anticipate clinical relapse in rheumatoid arthritis (RA) patients treated with rituximab

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A446-A446

2013

Volltextzugriff (PDF)

Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project

Fundamental & clinical pharmacology, 2009-02, Vol.23 (1), p.105-113

2009

Volltextzugriff (PDF)

A cryopyrin-associated periodic syndrome with joint destruction

Rheumatology (Oxford, England), 2007-04, Vol.46 (4), p.709-714

2007

Volltextzugriff (PDF)

SAT0044 Five-Year Favourable Outcome of Patients with Early Rheumatoid Arthritis in the 2000S: Data from the Espoir Cohort

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A595-A595

2013

Volltextzugriff (PDF)

OP0284 Impact of a Nurse Led Program of Patient Self-Assessment of Disease Activity on the Management of Rheumatoid Arthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial (Comedra)

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A150-A150

2013

Volltextzugriff (PDF)

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab

Rheumatology, 2007-03, Vol.46 (3), p.446-453

2007

Volltextzugriff (PDF)

Treatment of eosinophilic fasciitis with methotrexate

Journal of rheumatology, 1998-03, Vol.25 (3), p.606

1998

Volltextzugriff (PDF)

Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology

Annals of the rheumatic diseases, 2006-01, Vol.65 (1), p.45-50

2006

Volltextzugriff (PDF)

Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

Journal of clinical immunology, 2008-09, Vol.28 (5), p.445-455

2008

Volltextzugriff (PDF)

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Arthritis and rheumatism, 2010-09, Vol.62 (9), p.2625-2632

2010

Volltextzugriff (PDF)

1 – 25 von 324

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(177)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(178)
Female
(115)
Male
(106)
Middle Aged
(101)
Life Sciences & Biomedicine
(100)
Science & Technology
(100)
Adult
(80)
Aged
(75)
Rheumatology
(68)
Biological And Medical Sciences
(56)
Medical Sciences
(56)
Rheumatoid Arthritis
(34)
Diseases Of The Osteoarticular System
(30)
Sciences Biologiques Et Medicales
(29)
Sciences Medicales
(29)
Inflammatory Joint Diseases
(27)
Prospective Studies
(23)
Arthritis, Rheumatoid - Drug Therapy
(22)
Treatment Outcome
(20)
Pharmacology. Drug Treatments
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra)

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Usefulness of monitoring of B cell depletion in rituximab‐treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study

Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry

Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra

FRI0069 Performance of rapid radiographic progression prediction matrices in the early rheumatoid arthritis patients of the espoir cohort

Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome

Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis

Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three‐year prospective study in community‐recruited patients

AB0248 Clinical Significance of Soluble Vascular Endothelial-Cadherin and Anti-Vascular Endothelial-Cadherin Antibody in Rheumatoid Arthritis Treated with Etanercept or Adalimumab

FRI0154 Incidence of Cancers in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

OP0035 Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate)

FRI0215 Transitional and memory b cell analysis is an essential tool to anticipate clinical relapse in rheumatoid arthritis (RA) patients treated with rituximab

Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project

A cryopyrin-associated periodic syndrome with joint destruction

SAT0044 Five-Year Favourable Outcome of Patients with Early Rheumatoid Arthritis in the 2000S: Data from the Espoir Cohort

OP0284 Impact of a Nurse Led Program of Patient Self-Assessment of Disease Activity on the Management of Rheumatoid Arthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial (Comedra)

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab

Treatment of eosinophilic fasciitis with methotrexate

Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology

Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Suchergebnisse filtern